Protara Therapeutics Stock Performance
| TARA Stock | USD 4.60 0.02 0.43% |
The company holds a Beta of -0.9, which implies possible diversification benefits within a given portfolio. As the market becomes more bullish, returns on owning Protara Therapeutics are expected to decrease slowly. On the other hand, during market turmoil, Protara Therapeutics is expected to outperform it slightly. At this point, Protara Therapeutics has a negative expected return of -0.0749%. Please make sure to check Protara Therapeutics' accumulation distribution, and the relationship between the potential upside and day median price , to decide if Protara Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Protara Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, Protara Therapeutics is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 40.3 M |
Protara |
Protara Therapeutics Relative Risk vs. Return Landscape
If you would invest 515.00 in Protara Therapeutics on December 23, 2024 and sell it today you would lose (55.00) from holding Protara Therapeutics or give up 10.68% of portfolio value over 90 days. Protara Therapeutics is currently does not generate positive expected returns and assumes 4.7642% risk (volatility on return distribution) over the 90 days horizon. In different words, 42% of stocks are less volatile than Protara, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Protara Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Protara Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Protara Therapeutics, and traders can use it to determine the average amount a Protara Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0157
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | TARA |
Estimated Market Risk
| 4.76 actual daily | 42 58% of assets are more volatile |
Expected Return
| -0.07 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.02 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Protara Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Protara Therapeutics by adding Protara Therapeutics to a well-diversified portfolio.
Protara Therapeutics Fundamentals Growth
Protara Stock prices reflect investors' perceptions of the future prospects and financial health of Protara Therapeutics, and Protara Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Protara Stock performance.
| Return On Equity | -0.38 | ||||
| Return On Asset | -0.24 | ||||
| Current Valuation | 3.32 M | ||||
| Shares Outstanding | 36.77 M | ||||
| Price To Book | 1.01 X | ||||
| EBITDA | (49.15 M) | ||||
| Cash And Equivalents | 98.46 M | ||||
| Cash Per Share | 8.74 X | ||||
| Total Debt | 4.48 M | ||||
| Debt To Equity | 0.05 % | ||||
| Book Value Per Share | 4.77 X | ||||
| Cash Flow From Operations | (35.81 M) | ||||
| Earnings Per Share | (2.17) X | ||||
| Total Asset | 181.45 M | ||||
| Retained Earnings | (244.98 M) | ||||
About Protara Therapeutics Performance
By analyzing Protara Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Protara Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Protara Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Protara Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. Protara Therapeutics, Inc. is headquartered in New York, New York. Artara Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 31 people.Things to note about Protara Therapeutics performance evaluation
Checking the ongoing alerts about Protara Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Protara Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Protara Therapeutics generated a negative expected return over the last 90 days | |
| Protara Therapeutics has high historical volatility and very poor performance | |
| Net Loss for the year was (44.6 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Protara Therapeutics currently holds about 98.46 M in cash with (35.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.74, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 87.0% of the company shares are owned by institutional investors |
- Analyzing Protara Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Protara Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Protara Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Protara Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Protara Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Protara Therapeutics' stock. These opinions can provide insight into Protara Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Protara Stock analysis
When running Protara Therapeutics' price analysis, check to measure Protara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protara Therapeutics is operating at the current time. Most of Protara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protara Therapeutics' price. Additionally, you may evaluate how the addition of Protara Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |